Implementing Delabeling of Beta-Lactam Allergies: Getting to the “Why”?
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad152 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Bruce M Jones und 1 weiteren Autor:innen. Beteiligte Einrichtung: St. Joseph's/Candler Health System, Inc, Savannah, Georgia, USA. Hauptthemen laut MEDLINE: Penicillins, Hypersensitivity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
(See linked article by Trubiano JA et al., “The Who, What, When, and Where of Inpatient Direct Oral Penicillin Challenge—Implications for Health Services Implementation,” https://doi.org/10.1093/cid/ciad156) “With a big enough why you can overcome any how.” - James Clear To The Editor—We read with interest the article by Trubiano et al who detailed implementation of direct oral rechallenge for inpatients with a subjective listed penicillin allergy that was deemed very low risk [1]. An underappreciated and underused practice is expansion of services beyond penicillin skin testing (PST) to target lower-risk allergies, especially in resource-limited settings or where access to allergy/immunology is not readily available. The authors cover the important questions to ask, including that safety and positive impacts are already an assumed “why.” While we agree with this assessment and the known benefits to patients, as inpatient practitioners, the question we might ask is, “Why does it matter to us”? An important first step is to define who is “us.” Healthcare providers, namely, infectious diseases (ID) and allergy/immunology specialists, pharmacists, and nurses, play an important, collaborative role in allergy evaluation and delabeling. As Trubiano et al note, patients were detected and referred to the allergy team from a group that consisted of ID physicians, nurses, and pharmacists who completed the Antibiotic Allergy Assessment Tool [1]. We have previously demonstrated in our health system that a formalized process to assess patients with a listed penicillin allergy led to intervention and delabeling, while this was not the case without a formalized program [2]. Beyond delabeling of beta-lactam allergies, an often overlooked aspect is relabeling. Recent publications have shown that 36%–49% of inpatients who were penicillin skin–tested either still possessed the allergy label at discharge or had it added back within a year of testing [3–5]. This further indicates the need for greater emphasis on clarifying, delabeling, and preventing relabeling as a process and not a one-time event due to the multiplicity of prescribers and electronic health records in which a beta-lactam allergy can be added back and persist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. Joseph's/Candler Health System, Inc, Savannah, Georgia, USA.
- University of Georgia College of Pharmacy, Savannah, Georgia, USA.
ORCID-Profile: Bruce M Jones
Zitieren
APA
Jones, B. M., & Bland, C. M. (2023). Implementing Delabeling of Beta-Lactam Allergies: Getting to the “Why”?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad152
Vancouver
Jones BM, Bland CM. Implementing Delabeling of Beta-Lactam Allergies: Getting to the “Why”?. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad152
BibTeX
@article{Jones2023,
author = {Jones, Bruce M and Bland, Christopher M},
title = {Implementing Delabeling of Beta-Lactam Allergies: Getting to the “Why”?},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad152}
}
EUVIMED